Preparedness Strategy Provides BioPharmas an Opportunity to Mitigate Supply Chain Risks and Vulnerabilities While Initially Committing a Fraction of the Total Tech Transfer Investment Proactive ...

Over the past decade, 32% of innovative drug approvals were sponsored by emerging biotech companies, suggesting that they are ...

The global radiopharmaceutical CDMO market is anticipated to grow at an estimated rate of around 9% over the next five years.

Key market opportunities in the CDMO sector include rising outsourcing demands for biologics and HPAPIs, driven by R&D costs ...

Lifecore, a leading CDMO, specializes in sterile injectable pharmaceuticals and is poised to benefit from the growing CDMO market and potential GLP-1 opportunities. The company is doubling production ...

The lucrative cell and gene therapy (CGT) market is poised for dramatic growth that will likely drive revenues to nearly $37 billion/year by 2027. 1 Many companies who are actively moving forward in ...

BIOVECTRA, a part of Agilent Technologies Inc., is a leading North American CDMO specializing in biologics, mRNA therapeutics, and complex chemistry, proudly announces it is the recipient of the 2025 ...

Women in STEM bring diverse perspectives that are especially valuable in rare disease research. These conditions are complex and require innovative thinking. Attention to detail, empathy, and ...

Luca Alberici appointed to lead new Division offering focused technical innovation, product platform design, scalable manufacturing, and friendly customer experience for the underserved Advanced ...

Lifecore Biomedical has divested its food-related assets and now focuses solely on its high-quality CDMO business. The company faced a rough patch earlier this year but has since refinanced its debt, ...

New companies sometimes take years to get enough momentum to support an expansion. Ten23 health is not one of them. With today’s announcement of plans for a new facility, the CDMO is expanding twice ...